ReviewCurrent opinion in gastroenterology2014
Central role of IL-17/Th17 immune responses and the gut microbiota in the pathogenesis of intestinal fibrosis.
Review in Current opinion in gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 47 citations in OpenAlex.
- Article
- Diallyl disulfide attenuates DSS-induced colonic fibrosis in mice by modulating gut microbiota and Nrf2 signaling.Inflammopharmacology · 2025Article
- Molecular Basis of Chronic Intestinal Wall Fibrosis in Inflammatory Bowel Diseases.International journal of molecular sciences · 2025Review
- The effect of chronic inflammation on female fertility.Reproduction (Cambridge, England) · 2025Review
- Review
- Gut Microbiome and Organ Fibrosis.Nutrients · 2022Review
- Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy.Frontiers in immunology · 2022Review
- Novel mechanisms and clinical trial endpoints in intestinal fibrosis.Immunological reviews · 2021Review
- The role of dendritic cells derived osteoclasts in bone destruction diseases.Genes & diseases · 2021Review
- Total Flavone ofFrontiers in pharmacology · 2021Article
- Gut Microbiota as Regulators of Th17/Treg Balance in Patients With Myasthenia Gravis.Frontiers in immunology · 2021Review
- A porcine ligated loop model reveals new insight into the host immune response againstGut microbes · 2020Article
- Controversial Contribution of Th17/IL-17 Toward the Immune Response in Intestinal Fibrosis.Digestive diseases and sciences · 2020Review
- The Th17/Treg Cell Balance: A Gut Microbiota-Modulated Story.Microorganisms · 2019Review
- Article
- Irreversible effects of trichloroethylene on the gut microbial community and gut-associated immune responses in autoimmune-prone mice.Journal of applied toxicology : JAT · 2019Article
- Effect of Homocysteine on the Differentiation of CD4Digestive diseases and sciences · 2018Article
- IL-17-driven intestinal fibrosis is inhibited by Itch-mediated ubiquitination of HIC-5.Mucosal immunology · 2018Article
- Heat shock protein 70 protects mouse against post-infection irritable bowel syndrome via up-regulating intestinal γδ T cell's Th17 response.Cell & bioscience · 2018Article
- Genetic Adjuvantation of a Cell-Based Therapeutic Vaccine for Amelioration of Chagasic Cardiomyopathy.Infection and immunity · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
purpose of reviewIntestinal fibrosis is a serious, yet common, outcome in patients with inflammatory bowel disease (IBD). Despite advances in developing novel treatment modalities to control chronic gut inflammation characteristic of IBD, no effective antifibrotic therapies exist to date. As such, a deeper understanding of the molecular mechanisms underlying intestinal fibrosis and the availability of relevant animal models are critical to move this area of investigation forward. RECENT
findingsEmerging concepts in the pathogenesis of intestinal fibrosis include the central role of interleukin (IL)-17 and Th17 immune responses, although their precise contribution to chronic inflammation and IBD remains controversial. Other novel mediators of intestinal fibrosis, such as tumor necrosis factor-like ligand 1A and components of the renin-angiotensin system, support the importance of IL-17. Additionally, recent studies utilizing novel mouse models highlight the significance of the gut microbiota and link components of bacterial sensing, including nucleotide-binding oligomerization domain-containing protein 2, to IL-17/Th17 immune responses in the development of inflammation-associated intestinal fibrosis. SUMMARY: Recent progress in identifying key mediators, novel animal models, and important mechanistic pathways in the pathogenesis of intestinal fibrosis holds promise for the development of effective antifibrotics in an area of significant, unmet clinical need.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.